<?xml version="1.0" encoding="UTF-8"?>
<p id="par0040">Guidelines for hospitalized patients with influenza recommend the use of NAIs, which target neuraminidase, halting viral replication and decreasing the length of symptoms and mortality. Oseltamivir, zanamivir and peramivir are the NAIs approved for influenza treatment in the US and clinical efficacy seems comparable between them but previous attempts to use them in combination have not shown additional benefit [
 <xref rid="bib0030" ref-type="bibr">[6]</xref>, 
 <xref rid="bib0035" ref-type="bibr">[7]</xref>, 
 <xref rid="bib0040" ref-type="bibr">[8]</xref>]. Immunocompromised patients seem to be at increased risk of infection with NAI-resistant strains and also to develop severe disease [
 <xref rid="bib0045" ref-type="bibr">9</xref>]. Our diabetic patient was on chronic oral prednisone for her autoimmune nephropathy developed ARDS within 72 h from admission and required maximal ventilator settings, despite being on oseltamivir for three days. The use of zanamivir, was contraindicated because of the underlying asthma and IV peramivir was not available.
</p>
